STING1 and neoplasm: The anti-tumor effects of RT have been shown to be at least partially dependent on the immune response in vivo, and activation of a type I interferon (IFN) response by the cGAS/STING pathway has been implicated as a critical step in mediating this anti-tumor immune response [33–36].